Loading...
Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
BACKGROUND: Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. This phase I trial was conducted to determine the safety profile, maximal tolerated dose, and recommended phase II...
Na minha lista:
| Udgivet i: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5465458/ https://ncbi.nlm.nih.gov/pubmed/28595616 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3394-2 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|